Continuous Cardiac Output

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

NK
Nihon KohdenNEW YORK, NY
1 program
Correlation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver ResectionN/A
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Correlation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver ResectionN/A1 trial
Active Trials
NCT01443767Completed27Est. Nov 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Heidelberg PharmaCorrelation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection

Clinical Trials (1)

Total enrollment: 27 patients across 1 trials

NCT01443767Heidelberg PharmaCorrelation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection

Correlation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection

Start: Jul 2011Est. completion: Nov 201127 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space